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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness of oral vitamin C supplements to prevent and treat acute upper respiratory tract infections in adults and
children.
B A C K G R O U N D
Description of the condition
Upper respiratory tract infections (URTIs) comprise a number of
infections involving the nose, sinuses, pharynx, or larynx. Most
URTIs are caused by viruses, although bacteria (and much less
commonly fungi) can also be involved. Upper respiratory tract
infections are common; the ’common cold’ (which mainly affects
the nasal mucosa) is the most frequent presentation.
The burden of respiratory tract infections on individuals and on
society is high. On average, adults experience around 2.5 episodes
of each year, and children 3 to 6 episodes (Monto 2002). A UK
surveillance report found a weekly incidence of URTIs between
208 and 269 per 100,000 population (RCGP 2011). The total
cost of non-influenza viral respiratory illnesses to society is esti-
mated at USD 40,000 million annually, putting costs for respi-
ratory infections above chronic obstructive pulmonary disease or
congestive heart failure (Fendrick 2003). Lambert 2008 estimated
a mean cost of AUD 309 for all non-influenza URTIs in healthy
preschool-aged children.
The common cold is a mild upper respiratory illness that usu-
ally affects the nose, sinuses, throat, and larynx (Allan 2014). The
predominant symptoms are nasal, such as congestion and rhinor-
rhoea (nasal discharge), and sneezing, but sore throat and cough
are also often present (Allan 2014; Andrewes 1949; Eccles 2005;
Heikkinen 2003). A cold usually lasts between 7 and 10 days
(Heikkinen 2003). Observational studies estimate that in high-
income countries children have around six to eight colds per year,
and adults have between two and four annually (Gwaltney 2002;
Witek 2015). Common cold is a self limiting and benign illness,
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but due to its high prevalence (especially in autumn and winter),
common cold represents an important economic burden through
time off work and school, loss of productivity, and money spent
on medication and treatment (Bramley 2002; Hellgren 2010).
Acute rhinosinusitis is usually preceded by a cold, and viral rhinos-
inusitis is present in a significant proportion of people with rhi-
nosinusitis-like symptoms (Puhakka 1998). Few people (0.5% to
2%) develop bacterial rhinosinusitis (Berg 1986; Gwaltney 1996).
Rhinosinusitis is reported to affect approximately 16%of the adult
population in the USA (Anand 2004). Worrall 2011 reported an
incidence of acute sinusitis ranging from 15 to 40 episodes per
1000 patients per year, more commonly in adults than in chil-
dren, whose sinuses are not fully developed. A UK surveillance
report found between 0.7 and 1 new cases per 100,000 population
per week (RCGP 2011). In a meta-analysis of 29 studies, bacte-
ria were identified in approximately half of all isolates (Shintani
Smith 2015).
In acute otitis media, inflammation causes middle ear effusion,
resulting in symptoms such as ear pain, otorrhoea, or fever
(Lieberthal 2013). The annual incidence of acute otitis media is
estimated at 10.85%, representing 709 million cases worldwide,
with about 50% occurring in children under five years of age
(Monasta 2012). The highest burden of acute otitis media is found
in sub-Saharan Africa, South Asia, and Oceania, where the high-
est incidence of hearing impairment, a lasting consequence of fre-
quent acute otitis media, is also found (Monasta 2012). Weekly
incidence of acute otitis media in the UK ranges from 30 to 40
new cases per 100,000 population (RCGP 2011). There is evi-
dence to suggest that acute otitis media is often a direct result of a
respiratory infection (Elliot 2009). Bacteria, viruses, or both bac-
teria and viruses have been detected in the middle ear fluid of 96%
of people with acute otitis media (e.g. 66% bacteria and viruses
combined, 27% bacteria alone, and 4% virus alone) (Lieberthal
2013).
Acute pharyngitis or tonsillitis, or sore throat, is caused by viruses
or bacteria or both viruses and bacteria.Weekly incidence of tonsil-
litis/sore throat in the UK ranges from 55 to 80 per 100,000 pop-
ulation (RCGP 2011). The most common bacterial cause, group
A beta-haemolytic streptococcal infection (GABHS or GAS), ac-
counts for 15% to 30% of cases in children, and 5% to 15% in
adults (Vincent 2004). Ameta-analysis found a prevalence of GAS
in clinical settings of 25.2% (95% confidence interval (CI) 23.1
to 27.5) in children and 13.7% (95% CI 11.1 to 16.8) in adults,
with a higher prevalence in high-income countries compared with
low- to middle-income countries (Oliver 2018). Another meta-
analysis of studies in children found a pooled prevalence of GAS of
37%, with 24% in children aged under five years (Shaikh 2010).
Laryngitis presents with a hoarse voice in adults and adolescents
and is usually part of a non-specific URTI involving the nose and
throat. Laryngitis is mainly caused by virus, although some bac-
teria can be involved. When the trachea is involved, cough (dry,
productive, or both) is the predominant symptom, mostly based
on viral infection. In children aged under three years, croup is a
common presentation, which involves inflammation of the larynx
and trachea following a viral infection. The hallmark symptom is
a distinctive barking cough that commonly starts at night and can
progress to stridor and respiratory distress (Elliot 2009). Laryn-
gitis in adults is not well reported, but estimates of incidence for
all ages from the UK surveillance report range from 6 to 12 per
100,000 population per week (RCGP 2011). Croup typically af-
fects children aged under three years of age and is more common
in boys (Denny 1983).
Epiglottitis is an infection that typically affects very young chil-
dren whose airways are narrow. Epiglottitis can progress to poten-
tially life-threatening airway obstruction. A child with epiglotti-
tis typically presents drooling sitting upright and leaning forward
to make breathing easier (Isakson 2011). In countries where chil-
dren are vaccinated with the Haemophilus influenzae vaccine, the
main pathogen involved in epiglottitis, the condition is becoming
a rare presentation (Elliot 2009), and is now mostly seen in adults
(Isakson 2011). In a 16-year observational study, the overall inci-
dence of acute epiglottitis reduced from 4.5 cases/100,000/year to
0.98 cases/100,000/year after start of the vaccination programme
(Isakson 2011).
Description of the intervention
Vitamin C (ascorbic acid) is a water-soluble vitamin found in
fruit and vegetables, particularly in citrus fruit. Vitamin C plays
a crucial role in iron absorption, wound healing, collagen forma-
tion, production of neurotransmitters, and in improved glucose
metabolism (Yakoot 2011). The recommended dietary intake of
vitamin C for adults (aged over 18 years) is 45 mg per day, and
for children, 25 mg/day up to 6 months; 30 mg/day between 7
and 12 months; 35 mg/day for 1 to 8 years; and 40 mg/day for
children aged 9 to 18 years (Australian Government 2017). Vita-
min C deficiency is associated with scurvy. Scurvy is linked with
high risk of pneumonia, which in turn has triggered interest in
the effect of vitamin C on respiratory tract infections (Anderson
1974; Hemilä 2009). Vitamin C is acquired through a healthy
diet, but a number of dietary supplements are available over the
counter. In this review we will consider the efficacy and safety of
vitamin C taken as an oral supplement to a normal diet.
How the intervention might work
Vitamin C plays a crucial role in iron absorption, wound heal-
ing, collagen formation, production of neurotransmitters, and im-
proved glucose metabolism (Yakoot 2011). Themechanism for re-
duction of the incidence and severity of URTIs may be through an
improved immune system. Vitamin C has antioxidant properties
and protects the immune system against oxidative stress generated
during infections (Hemilä 2017;Webb 2007). Studies have shown
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that high levels of serum vitamin C are associated with enhanced
antibody response, neutrophil function, and mitogenic response.
Furthermore, in vitro models suggest that vitamin C inhibits rhi-
noviruses (Webb 2007). The reduction in vitamin C levels ob-
served during infection suggests that supplementing vitamin C
could have a positive impact on preventing and treating infections
(Hemilä 2017). This hypothesis is supported by a Swedish cohort
study of 2237 adults aged 25 to 64 years showing that women with
a high daily intake of vitamin C in their diet (≥ 110 mg/day) ex-
perienced fewer URTIs over a nine month period than those with
lower dietary intake. However, there was no association of vitamin
C intake and URTI incidence in men (Raposo 2017). Authors of
a systematic review and meta-analysis of vitamin C supplemen-
tation in children concluded that vitamin C was not effective in
preventing URTIs, but reduced URTI duration by approximately
1.6 days (Vorilhon 2018).
In this review, prevention refers to healthy participants with no
signs and symptoms of aURTI taking oral vitaminC supplements.
Treatment refers to initiating oral vitaminC supplementationonce
URTI signs and symptoms arise.
Why it is important to do this review
VitaminCachieved popularity as a treatment for the commoncold
following the 1970publicationofVitaminCand theCommonCold
(Pauling 1970). Pauling described a meta-analysis of four trials,
and concluded there was strong evidence that vitamin C reduced
the incidence and severity of the common cold. Conversely, others
have concluded that the apparent benefit of vitamin C can be
explained by the placebo effect (Chalmers 1975; Dykes 1975;
Karlowski 1975). Skepticism about the benefits of vitamin C as a
treatment for the common cold or other URTIs remains.
A previousCochrane Review evaluated the effectiveness of vitamin
C for preventing and treating the common cold and found no
evidence to support taking vitamin C to prevent or treat common
colds (Hemilä 2013). In light of high consumer interest in over-
the-counter treatments such as vitamin C for a wide range of
respiratory infections, this review has a broader perspective and
includes URTIs as well as the common cold. We will also include
subgroup analyses and report on specific symptoms that may be
relevant to patients (e.g. nasal congestion, headache, fever, and
sore throat).
O B J E C T I V E S
Toassess the effectiveness of oral vitaminC supplements to prevent
and treat acute upper respiratory tract infections in adults and
children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include double-blind randomised controlled trials (RCTs).
We will not consider non-randomised or quasi-randomised trials
or unblinded studies because these designs introduce high risk of
bias. We will consider cluster-RCTs where participants are ran-
domised at the cluster level and outcomes are measured at the in-
dividual level.
We will include studies reported as full text, those published as
abstract only, and unpublished data.
Types of participants
Prevention of URTIs
We will include healthy adults and children of all ages regardless
of gender who have not been diagnosed with a URTI or other
respiratory infection.
Treatment of URTIs
We will include adults and children of all ages regardless of gender
with a URTI (symptoms of a URTI for no more than seven days
before study commencement). The following URTIs will be eligi-
ble for inclusion in the review: common cold, rhinosinusitis, acute
otitis media, acute pharyngitis or tonsillitis, laryngitis, tracheitis,
or epiglottitis. We will exclude participants with a diagnosis of
another upper respiratory condition (such as influenza) or with
lower respiratory tract infections.
Types of interventions
We will include trials comparing oral vitamin C administration
(any dose) daily with placebo, irrespective of usual dietary in-
take. We will include only placebo-controlled comparisons be-
cause studies comparing the intervention with no treatment may
overestimate the effect of the active treatment. We will describe
the nature of the placebo used because it may be challenging to
produce placebos for dissolving tablets. We will consider all time
frames for duration of prevention and treatment.
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Types of outcome measures
Primary outcomes
Prevention of URTIs
1. Incidence of URTIs during the study period (expressed as a
proportion of participants who experience a URTI or the
number of URTIs over a period of time, or both).
2. Adverse events, such as diarrhoea, nausea, vomiting,
heartburn, abdominal symptoms, headache, insomnia, flushing,
etc.
Treatment of URTIs
1. Time to resolution of overall symptoms; we will also
consider measures that combine duration and severity (e.g. area
under the curve of severity by time).
2. Adverse events, such as diarrhoea, nausea, vomiting,




1. Time to occurrence of URTI.
2. Severity of subjective symptoms (overall symptoms, nasal
congestion, sneezing, rhinorrhoea, headache, sore throat, and
fever). We will also consider measures that combine duration and
severity of specific symptoms (e.g. area under the curve of
severity by time). Severity may be measured using Likert scales,
visual analogue scales (VAS), or other validated instruments.
3. Time to return to work or school.
4. Patient satisfaction.
Treatment of URTIs
1. Duration of subjective symptoms (nasal congestion,
sneezing, rhinorrhoea, headache, sore throat, and fever).
2. Severity of subjective symptoms (overall symptoms, nasal
congestion, sneezing, rhinorrhoea, headache, sore throat, and
fever). We will also consider measures that combine duration and
severity of specific symptoms (e.g. area under the curve of
severity by time). Severity may be measured using Likert scales,
VAS, or other validated instruments.
3. Time to return to work or school.
4. Patient satisfaction.
Reporting one or more of the listed outcomes in the trial is not an
inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will search the following databases.
• CENTRAL (Cochrane Central Register of Controlled
Trials), which contains the Cochrane Acute Respiratory
Infections (ARI) Group’s Specialised Register
• MEDLINE
• Embase
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature)
• Web of Science
We will use the search strategy described in Appendix 1 to search
MEDLINE. We will combine the MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for randomised tri-
als: sensitivity and precision-maximising version (2008 revision)
(Lefebvre 2011). We will modify the MEDLINE search to run in
the other listed databases.
We will also conduct searches of the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov (
clinicaltrials.gov) and the World Health Organization ( WHO)
International Clinical Trials Registry Platform ( ICTRP) (
apps.who.int/trialsearch/). We will not impose language or publi-
cation restrictions.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references. We will contact experts in the
field to identify additional unpublished materials.
Data collection and analysis
Selection of studies
Three review authors (LD, ET, EB)will independently screen titles
and abstracts for inclusion of all the potential studies identified as
a result of the search. All citations will be screened by at least two
review authors.
We will retrieve the full-text study reports/publications of studies
deemed potentially eligible, and three review authors (LD, ET,
EB) will independently screen the full texts and identify studies
for inclusion, and record reasons for exclusion of the ineligible
studies. Any disagreements will be resolved through discussion
or by consulting a fourth review author (MVD) if necessary. We
will identify and exclude duplicates and collate multiple reports
of the same study so that each study, rather than each report, is
the unit of interest in the review. We will record the selection
process in sufficient detail to complete a PRISMA flow diagram
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and ’Characteristics of excluded studies’ table (Moher 2009). We
will not impose any language restrictions.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data that has been piloted on at least one study in the
review. One review author (ET) will extract study characteristics
from the included studies. We will extract the following study
characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, information on usual dietary intake of vitamin C,
inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Three review authors (LD, ET, EPH) will independently extract
outcome data from the included studies.Wewill note in the ’Char-
acteristics of included studies’ table if outcome data are not re-
ported in a useable way. Any disagreements will be resolved by
consensus or by involving a fourth review author (ADS). One re-
view author (LD) will enter data into Review Manager 5 (Review
Manager 2014). We will double-check that data are entered cor-
rectly by comparing the data presented in the systematic review
with the study reports. A second review author (ET) will spot-
check study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Three review authors (ET, EB, ADS) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements will be resolved by discussion or by involving
another review author (MVD).Wewill assess risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low, or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes, where necessary. Where information
on risk of bias relates to unpublished data or correspondence with
a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will enter the outcome data for each study into the data tables
in Review Manager 5 to calculate the treatment effects (Review
Manager 2014). We expect that studies will report our primary
outcome in different ways.
We will use the followingmeasures of effect for prevention studies.
• Incidence of URTI (primary outcome 1): risk ratio (RR)
where the proportion of participants experiencing a URTI is
reported, and rate ratio where rates of infections per unit of time
are reported.
• Adverse events (primary outcome 2): RR where the
proportion of participants experiencing any or a specific adverse
event is reported.
• Time to occurrence of URTI (secondary outcome 1):
hazard ratios where the data are provided as a time to event.
• Severity of subjective symptoms (secondary outcome 2):
standardised mean difference (SMD) where this is reported on a
continuous or ordinal scale.
• Time to return to work or school (secondary outcome 3):
hazard ratios where the data are provided as a time to event,
SMD where this is reported as number of days (or hours).
• Patient satisfaction (secondary outcome 4): RR where the
proportion of participants who are satisfied is reported and
standardised mean difference (SMD) where patient satisfaction is
reported on a continuous scale.
We will use the following measures of effect for treatment studies.
• Time to resolution of URTI (= duration of illness) (primary
outcome 1): SMD where this is reported as number of days (or
hours).
• Adverse events (primary outcome 2): RR where the
proportion of participants experiencing any or a specific adverse
event is reported.
• Duration of subjective symptoms (secondary outcome 1):
SMD where this is reported as number of days (or hours).
• Severity of subjective symptoms (secondary outcome 2):
SMD where this is reported as number of days (or hours).
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• Time to return to work or school (secondary outcome 3):
hazard ratios where the data are provided as a time to event.
• Patient satisfaction (secondary outcome 4): RR where the
proportion of participants who are satisfied is reported and SMD
where patient satisfaction is reported on a continuous scale.
We will undertake meta-analyses only where this is meaningful,
that is if the treatments, participants, and the underlying clinical
question are similar enough for pooling to make sense.
Wewill usemeta-regression to explore a dose-response relationship
if we find a sufficient number of studies. We will illustrate these
results in forest plots by subgroup of dose (≤ 0.45 g, > 0.45 g)
(Australian Government 2017).
Unit of analysis issues
If we find cluster or cross-over trials, we will use the methods
recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). If there are studies with more
than one dose used, we will combine all active treatment arms
and compare with the placebo/no treatment arm for the main
comparisons. However, if possible wemay use dose data in analysis
of dose-response.
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
where possible (e.g. when a study is identified as abstract only).
Where this is not possible, and the missing data are thought to in-
troduce serious bias, we will explore the impact of including such
studies in the overall assessment of results by a sensitivity analysis.
If numerical outcome data such as standard deviations or correla-
tion coefficients are missing and cannot be obtained from the trial
authors, we will calculate them from other available statistics, such
as P values, according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity, we
will report it and explore possible causes by prespecified subgroup
analysis.Wewill consider an I² statistic of 50%ormore to represent
important heterogeneity. We will explore the causes of statistical
heterogeneity using sensitivity analyses. We will not carry out a
meta-analysis if heterogeneity is greater than 90% and there is
too much variation in the results, particularly inconsistency in the
direction of the effect.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small-study and publication
biases.
Data synthesis
We will pool data from studies we judge to be clinically homoge-
neous using Review Manager 5 software (Review Manager 2014).
If more than one study provides useable data for any single com-
parison, we will perform a meta-analysis. We will present meta-
analyses separately for prevention and treatment trials. If meta-
analysis is not possible, we will report a summary of data from
individual studies. We will use random-effects models, as we ex-
pect the ways of measuring the outcome to differ, and there to
be a range of doses. We will also use a random-effects model to
pool study data reported as time-to-event rates (i.e. for the primary
outcome of ’time to resolution of symptoms’ in treatment trials
and for the secondary outcome ’time to occurrence of URTI’ in
prevention trials). We will use the log rank method to obtain a
hazard ratio as a pooled estimate of effect (Higgins 2011).
GRADE and ’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes for the prevention trials:
1. URTI incidence;
2. adverse events (proportion of total adverse events reported);
3. time to occurrence of URTI;
4. patient satisfaction.
For the treatment trials we will include:
1. time to resolution of symptoms;
2. adverse events (proportion of total adverse events reported);
3. duration of symptoms;
4. severity of symptoms;
5. time to return to work or school;
6. patient satisfaction.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness, and publication
bias) to assess the quality of a body of evidence as it relates
to the studies that contribute data to the meta-analyses for the
prespecified outcomes (Atkins 2004). We will use the meth-
ods and recommendations described in Section 8.5 and Chap-
ter 12 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011), employing GRADEpro GDT software
(GRADEpro GDT). We will justify all decisions to down- or up-
grade the quality of the evidence using footnotes, and wewill make
comments to aid the reader’s understanding of the review where
necessary.
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Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses:
1. adults and children (< 12 years of age);
2. specific URTIs (e.g. tonsillitis, otitis media, rhinosinusitis,
etc.);
3. different vitamin C doses (lower or higher than the
recommended daily dose, i.e. ≤ 0.45 g and > 0.45 g);
4. therapeutic studies with and without concomitant
symptomatic medication; and
5. smokers versus non-smokers.
Wewill use theChi² test to test for subgroup interactions inReview
Manager 5 (Review Manager 2014).
Sensitivity analysis
We will perform sensitivity analyses to assess the impact of het-
erogeneity on the overall outcome (pooled estimate) of the meta-
analysis. We will do this by gradually removing single trials to in-
vestigate the extent to which they contribute to heterogeneity. We
will also use sensitivity analyses to assess the impact of risk of bias
on the overall pooled estimate by first pooling the studies with
low risk of bias and then gradually adding the studies assessed as
having a high risk of bias.
A C K N OW L E D G E M E N T S
The methods section of this protocol is based on a standard tem-
plate developed by the Cochrane Airways Group and adapted by
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
(“Ascorbic Acid”[Mesh] OR “ascorbic acid”[tiab] OR “vitamin c”[tiab] OR “vit c”[tiab])
AND
(“Respiratory Tract Infections”[Mesh] ORNasopharyngitis[Mesh] ORRhinitis[Mesh] OR Sinusitis[Mesh] OR Pharyngitis[Mesh] OR
Laryngitis[Mesh]ORbronchitis[Mesh]ORbronchiolitis[Mesh]OR“bronchiolitis, viral”[Mesh]ORPleurisy[Mesh]ORCough[Mesh]
OR Sneezing[Mesh] OR Pneumonia[Mesh] OR “Respiratory Sounds”[Mesh] OR “Otitis Media”[Mesh] OR Earache[Mesh] OR “In-
fluenza, Human”[Mesh] OR “Common Cold”[Mesh] OR “Respiratory infection”[tiab] OR “Respiratory infections”[tiab] OR “Res-
piratory Tract Infections“[tiab] OR “Respiratory Tract Infection”[tiab] OR “Respiratory inflammation”[tiab] OR “Respiratory tract
inflammation”[tiab] OR urti[tiab] OR lrti[tiab] OR ari[tiab] OR nasopharyngitis[tiab] OR rhinopharyngitis[tiab] OR sinusitis[tiab]
OR nasosinusitis[tiab] OR rhinosinusitis[tiab] OR rhinitis[tiab] OR rhinorrhoea[tiab] OR rhinorrhea[tiab] OR pharyngitis[tiab] OR
“sore throat”[tiab] OR Tonsillitis[tiab] OR laryngitis[tiab] OR croup[tiab] OR pseudocroup[tiab] OR tracheobronchitis[tiab] OR
laryngotracheobronchitis[tiab] OR bronchitis[tiab] OR bronchiolitis[tiab] OR pneumonia[tiab] OR pleuropneumonia[tiab] OR bron-
chopneumonia[tiab] OR pleurisy[tiab] OR cough[tiab] OR Wheeze[tiab] OR Wheezing[tiab] OR “otitis media”[tiab] OR aom[tiab]
OR ome[tiab] OR earache[tiab] OR influenza[tiab] OR flu[tiab] OR “common cold”[tiab] OR “common colds”[tiab])
AND
(Randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR
“drug therapy”[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab])
NOT
(Animals[Mesh] not (Animals[Mesh] and Humans[Mesh]))
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